Vnitr Lek 2026, 72(6):402-411 | DOI: 10.36290/vnl.2026.074

Cushing's syndrome: current view

Michal Kršek
III. interní klinika-klinika endokrinologie a metabolismu,
1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Cushing's syndrome is a rare endocrine disorder that significantly affects patients and is associated with significantly increased morbidity and mortality, mainly due to cardiovascular disorders and complications. Increased morbidity and mortality persist even many years after the successful cure. Therefore, early diagnosis and treatment are of eminent importance. It is necessary to state that diagnosis and differential diagnosis of Cushing's syndrome belong to the most difficult ones in clinical endocrinology mainly for variable aetiology and also not sufficiently good performance of diagnostic tests. That also pays for the treatment that often has to be complex and has to include also the treatment of comorbidities.

Keywords: Cushing's syndrome, clinical presentation, diagnosis, treatment.

Accepted: September 15, 2026; Published: October 2, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kršek M. Cushing's syndrome: current view. Vnitr Lek. 2026;72(6):402-411. doi: 10.36290/vnl.2026.074.
Download citation

References

  1. Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137-195.
  2. Lindholm J, Juul S, Jørgensen JO. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117-123. Go to original source... Go to PubMed...
  3. Extabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484. Go to original source...
  4. Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281-293. Go to original source... Go to PubMed...
  5. Reincke M, Fleseriu M. Cushing syndrome: A review. JAMA. 2023;330(2):170-181. Go to original source... Go to PubMed...
  6. Gadelha M, Gatto F, Wildemberg LE, et al. Cushing's syndrome. Lancet. 2023;402:2237-2252. Go to original source... Go to PubMed...
  7. Araujo-Castro M, Marazuela M. Cushing's syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease. Frontiers in Endocrinology. 2022;13:913253. Go to original source... Go to PubMed...
  8. Nieman LK, Castinetti F, Newell-Price J, et al. Cushing syndrome. Nat Rev Dis Primers. 2025;11(1):4. Go to original source... Go to PubMed...
  9. Pivonello R, De Martino MC, De Leo M, et al. Cushing's syndrome: aftermath of cure. Arq Bras Endocrinol Metabol. 2007;51:1381-1391. Go to original source... Go to PubMed...
  10. Ferraú F, Korbonits M. Metabolic comorbidities in Cushing's syndrome. Eur J Endocrinol. 2015;173:M133-M157. Go to original source... Go to PubMed...
  11. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. Go to original source... Go to PubMed...
  12. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875. Go to original source... Go to PubMed...
  13. Hinojosa-Amaya JM, Varlamov EV, McCartney S, et al. Hypercortisolemia recurrence in Cushing's disease: a diagnostic challenge. Front Endocrinol (Lausanne). 2019;10:740. Go to original source... Go to PubMed...
  14. Petersenn S. Biochemical diagnosis of Cushing's disease: Screening and confirmatory testing. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101519. Go to original source... Go to PubMed...
  15. Utz AL, Swearingen B, Biller BM. Pituitary surgery and postoperative management in Cushing's disease. Endocrinol Metab North Am. 2005;34:459-478. Go to original source... Go to PubMed...
  16. McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol. 1996;44:1-6. Go to original source... Go to PubMed...
  17. Marek J, Ježková J, Hána V, et al. Gamma knife radiosurgery for Cushing's disease and Nelson's syndrome. Pituitary. 2015;18:376-384. Go to original source...
  18. Fassnacht M, Libe R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update. Nature Rev Endocrinol. 2011;7:323-335. Go to original source... Go to PubMed...
  19. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551-4564. Go to original source... Go to PubMed...
  20. de Bruin C, Feelders RA, Lamberts SW, et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Rev Endocr Metab Disord. 2009;10:91-102. Go to original source... Go to PubMed...
  21. Kam BL, Teunissen JJ, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):103-112. Go to original source...
  22. Godboud A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;165:709-716. Go to original source... Go to PubMed...
  23. Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment of Cushing's disease. Clin Diabetes Endocrinol. 2016;2:16. Go to original source... Go to PubMed...
  24. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol. 1991;25:398-400. Go to original source... Go to PubMed...
  25. Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary. 2016;19:643-653. Go to original source... Go to PubMed...
  26. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178. Go to original source...
  27. Fleseriu M, Newell-Price J, Pivonello R, et al. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. Eur J Endocrinol. 2022;187:531-541. Go to original source... Go to PubMed...
  28. Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab. 2022;107:e2882-e2895. Go to original source... Go to PubMed...
  29. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in consecutive series of 96 patients. Br J Cancer. 1994;69:947-951. Go to original source... Go to PubMed...
  30. Drake WM, Perry LA, Hinds CJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolaemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab. 1998;83:3542-3544. Go to original source...
  31. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.